1.	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
2.	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PETHEMA-LAM07, NCT01041040
3.	Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 61 and over Sponsor: Other Protocol IDs: EORTC-06031, NCT00091234
4.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
5.	Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MYFLAI07, NCT00909168
6.	Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AMLSG 09-09, NCT00893399
7.	Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: EK 92062003, NCT00460447
8.	Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 07-154, NCT00660036
9.	A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 090516, NCT00766116
10.	S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000572619, S0535, U10CA032102, SWOG-S0535, NCT00551460
11.	Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0147, NCT00801489
12.	Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 50 and over Sponsor: Other Protocol IDs: 2009-08-029, NCT01039363
13.	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2240.00, NCI-2010-00281, P01CA078902, NCT01083706
14.	Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 2010-0981, NCT01409161